Needham & Company LLC Reiterates “Hold” Rating for Omeros (NASDAQ:OMER)

Omeros (NASDAQ:OMER)‘s stock had its “hold” rating reissued by equities researchers at Needham & Company LLC in a report issued on Wednesday, AnalystRatings.com reports.

Several other research analysts have also recently weighed in on OMER. BidaskClub cut Omeros from a “sell” rating to a “strong sell” rating in a research note on Saturday, October 12th. Zacks Investment Research cut Omeros from a “buy” rating to a “hold” rating in a research note on Wednesday, October 30th. Wedbush reaffirmed a “hold” rating and set a $18.00 target price on shares of Omeros in a research note on Monday, October 28th. HC Wainwright reaffirmed a “buy” rating and set a $35.00 target price on shares of Omeros in a research note on Tuesday, November 5th. Finally, Maxim Group set a $32.00 target price on Omeros and gave the company a “buy” rating in a research note on Friday, August 9th. Three equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company. The company has an average rating of “Hold” and an average target price of $25.60.

Shares of OMER traded down $0.61 during trading on Wednesday, reaching $13.20. The company’s stock had a trading volume of 525,200 shares, compared to its average volume of 478,581. The company has a fifty day moving average of $15.37 and a two-hundred day moving average of $16.90. Omeros has a twelve month low of $10.30 and a twelve month high of $20.92. The company has a market cap of $687.02 million, a price-to-earnings ratio of -5.95 and a beta of 2.78.

Omeros (NASDAQ:OMER) last announced its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.41) by $0.08. The firm had revenue of $29.86 million for the quarter, compared to the consensus estimate of $27.19 million. During the same period in the prior year, the business earned ($0.81) EPS. The company’s quarterly revenue was up 547.7% compared to the same quarter last year. On average, analysts anticipate that Omeros will post -1.2 earnings per share for the current fiscal year.

In related news, Director Thomas J. Cable sold 5,000 shares of the stock in a transaction on Monday, October 14th. The stock was sold at an average price of $15.12, for a total value of $75,600.00. Following the completion of the transaction, the director now owns 35,067 shares in the company, valued at approximately $530,213.04. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 12.80% of the company’s stock.

Several large investors have recently added to or reduced their stakes in OMER. Nuveen Asset Management LLC acquired a new position in shares of Omeros in the 2nd quarter valued at $3,221,000. Chicago Equity Partners LLC acquired a new position in shares of Omeros in the 2nd quarter valued at $1,094,000. Ingalls & Snyder LLC boosted its position in shares of Omeros by 1.2% in the 3rd quarter. Ingalls & Snyder LLC now owns 5,023,755 shares of the biopharmaceutical company’s stock valued at $82,038,000 after purchasing an additional 58,198 shares during the period. Virtus ETF Advisers LLC acquired a new position in shares of Omeros in the 2nd quarter valued at $784,000. Finally, SG Americas Securities LLC boosted its position in shares of Omeros by 61.0% in the 3rd quarter. SG Americas Securities LLC now owns 130,823 shares of the biopharmaceutical company’s stock valued at $2,136,000 after purchasing an additional 49,548 shares during the period. Institutional investors and hedge funds own 53.46% of the company’s stock.

Omeros Company Profile

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.

Featured Story: Real Estate Investment Trust (REIT) ETF

Analyst Recommendations for Omeros (NASDAQ:OMER)

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.